Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Rhea-AI Summary

Hemogenyx Pharmaceuticals plc announces that the total issued share capital of the Company is 1,153,065,988 ordinary shares of 1 pence each, with no shares held in treasury. The total number of voting rights in the Company is also 1,153,065,988.

LONDON, UK / ACCESSWIRE / October 31, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 October 2023 consists of 1,153,065,988 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,153,065,988.

The figure of 1,153,065,988 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/797909/hemogenyx-pharmaceuticals-plc-announces-total-voting-rights

FAQ

What is the total issued share capital of Hemogenyx Pharmaceuticals plc?

The total issued share capital of Hemogenyx Pharmaceuticals plc is 1,153,065,988 ordinary shares of 1 pence each.

Are there any shares held in treasury by Hemogenyx Pharmaceuticals plc?

No, there are no shares held in treasury by Hemogenyx Pharmaceuticals plc.

What is the total number of voting rights in Hemogenyx Pharmaceuticals plc?

The total number of voting rights in Hemogenyx Pharmaceuticals plc is 1,153,065,988.

What are the Financial Conduct Authority's Disclosure Guidance and Transparency Rules?

The Financial Conduct Authority's Disclosure Guidance and Transparency Rules are regulations that require shareholders to notify their investment in, or a change in their interest in, the share capital of a company.

Who can be contacted for further information about Hemogenyx Pharmaceuticals plc?

For further information about Hemogenyx Pharmaceuticals plc, please contact Dr Vladislav Sandler, Chief Executive Officer & Co-Founder at headquarters@hemogenyx.com or Peter Redmond, Director at peter.redmond@hemogenyx.com.

Which corporate finance firms are involved with Hemogenyx Pharmaceuticals plc?

SP Angel Corporate Finance LLP and Peterhouse Capital Limited are involved with Hemogenyx Pharmaceuticals plc.